The media relations efforts from Alliance staff and researchers are designed to alert the public about the vital work happening across our network. When we share stories about clinical trial results, scientific milestones, and investigator achievements, we are showcasing the real-world progress you help make possible.
See where the Alliance was mentioned in October 2026 in the links below.
Alliance trial results
Alliance ATOMIC trial leads to FDA approval of atezolizumab with chemotherapy for stage 3 dMMR colon cancer
Based on the results of the ATOMIC trial (Alliance A021502) led by Frank Sinicrope, MD, and published in the New England Journal of Medicine, the FDA has approved atezolizumab in combination with chemotherapy for the adjuvant treatment of adults and children 2 years and older with stage IIImismatch repai-r deficient (dMMR) colon cancer, reported Yahoo! Finance, New York Newscast, Las Vegas Sun, Financial Times, Pittsburgh Post-Gazette, Minnesota Star Tribune, KIMT 3, WRAL News, ASCO Post, Healio, Cancer Today, Pilot News, Wapakoneta Daily News, Poteau Daily News, Barre Montpelier Times Argus, Valley City Times Record, Daily Independent, Evening Leader, Human Progress, American Journal of Managed Care, Evening Leader, Mega Doctor News, Bingham News, Cancer Network, Cure Today, OncLive, Oncology Nursing News, MedPage Today, We Trials, FirstWordPharma, Medical News Alert, Trading View, Newswise, Mayo Clinic News, Pharmaceutical Technology, Doctor Discover, GuruFocus, Rutland Herald, PharmExec, Bioengineer, BioScience Desk, Science Magazine, RTT News, Weekly Reviewer, USA News Hour, BrightSurf, BioSpace, Stock Titan, Health Today, Science Frontiers Daily, Patient Worthy, Targeted Oncology, Z106.3 Radio, Stockwatch, Medical Daily, Investing News, Street Insider, Morningstar, Trading View, Crain Business, Clinical Trial Vanguard, Business Insurance, Benzinga, Globe and Mail, AllSci, World Today Journal, Washington Magazine, New Jersey Headlines, Texas News Headlines, California News Reporter, Kansas News Headlines, Wisconsin Chronicle, Montpelier Journal, Live Wire Reporter, Oklahoma News Online, Richmond News Now, Wyoming News Headlines, Harrisburg News Now, Annapolis News Updates, Honolulu News Now, North Carolina News Headlines, Via News, Concord News Now, Half the Hazard, Australia’s Investing.com, Austria’s Baha Breaking News, Canada’s Le Lezard, China’s News Yaozh and Market Pulse, Denmark’s Via Ritzau, Finland’s Kauppalehti, Germany’s ADVFN, Forschung und Wissen and Finanz Nachrichten, Hong Kong’s Sina, India’s Pharma Post, Pharma Shots and Voice of Healthcare, Italy’s Eventi and Science Chronicles, Ireland’s OncoAssist, UK’s Europe Says, EuropaWire, European Pharmaceutical Review, Daily London, UK NewsHour, Apex Onco, LabioTech, and Daily Cardiff, Romania’s Romedic, Singapore’s B2B Asia News, Weekender, Spain’s Pharmacy and Health, Sweden’s Today’s Industry, and MarketScreener, and Taiwan’s Taiwan News. Read the Alliance news story.
Alliance RT CHARM trial finds three weeks of breast radiation as good as five weeks for women wanting breast reconstruction after surgery
Results the RT CHARM trial (Alliance A221505) published in the Journal of Clinical Oncology found that a shorter, three-week course of radiation after mastectomy is as safe and effective as the traditional five-week schedule for women undergoing breast reconstruction, without compromising reconstruction outcome, reported U.S. News and World Report, HealthDay, Cure Today, Newsmax Health, Medical Xpress, Science Magazine, Memesita, Medscape, Drugs.com, Medicine.net, Be Well, Bright Surf, Life Technology, OncoDaily, Argentina’s Extra Catamarca, Germany’s Biermann Medizin, Korea’s MD Today, Global Biz News, and Alpha Biz, and Mexico’s El Tiempo, Infobae, Lado, and HealthDaySpanish. Read the Alliance news story.
Alliance trial awareness
AFT launches phase III trial using advanced blood testing to personalize treatment for early-stage breast cancer
Alliance Foundation Trials, LLC (AFT) announced the launch of AFT-70 NAVIGATE, a randomized phase III trial evaluating a novel molecular residual disease (MRD)-guided treatment strategy for patients with intermediate and high-risk ER-positive/HER2-negative early breast cancer. The trial is sponsored and led by AFT, with collaboration and co-funding from Natera and Genentech, a member of the Roche Group, reported Yahoo News!, MedPath, GenomeWeb, News Medical, Bioengineer, BioSpace, Science Magazine, Market Screener, Business Wire, The Joplin Globe, Mid-Florida Newspapers, First Word Pharma, Woonsocket Call, Pilot News, Weiss Research, OncoDaily, Pharma Daily, AllSci, Lifestyle, Ticker Report, Patch.com, Webull, Capital.com, StockTitan, StreetInsider, Canada’s Investing.com, China’s Zonebourse, Germany’s Ad Hoc News, Goldesel, and VermoegensZentrum, and UK’s Head Topics. Read the news story.
Breast Cancer Awareness Month: Advancing breast cancer research through clinical trials
Clinical trials play a vital role in improving treatments and screening for breast cancer. As part of the National Clinical Trials Network, the Alliance for Clinical Trials in Oncology works to advance cancer research and expand access to promising screening strategies and treatments. The Alliance and Alliance Foundation Trials (AFT) currently have eight active trials open to people with breast cancer, reports Bioengineer, Science Magazine, Bright Surf, EurekAlert and Korea’s Economy Today and Mediadale. Read the Alliance news story.
Alliance ERASur trial expands outside the U.S.
The ERASur trial (Alliance A022101), which explores total ablative therapy for limited metastatic colorectal cancer, is now available at sites in several countries outside the United States, reported OncoDaily. Read the Alliance news story.
Alliance ShortStop HER2 study now enrolling
Led by Adrienne Waks, of the Dana-Farber Cancer Institute, Alliance A012303 (ShortStop HER2) a phase III clinical trial now open for enrollment through the Alliance for Clinical Trials in Oncology, reports OncoDaily. This study asks if people with early-stage HER2 positive breast cancer who have no cancer left after neoadjuvant chemotherapy and HER2 targeted therapy, can safely have less treatment after surgery.Add your story content here.